Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Https://www.pharmiweb.com/press-release/2021-01-21/covid-19-testing-sector-demand-set-to-continue-amid-vaccine-rollout
"COVID-19 TESTING SECTOR DEMAND SET TO CONTINUE AMID VACCINE ROLLOUT
London 21 January 2021 – The diagnostics sector will continue to see growth in 2021 as demand for COVID-19 testing continues to surge. It has been suggested that to ensure effective disease control, the UK alone would require 120m tests per month. Global demand exceeds supply, providing opportunities for existing diagnostics providers and newcomers alike. The diagnostics sector remains a high-growth area, at a time when most other sectors are experiencing disruptions due to the pandemic.
These are the findings of finnCap’s new quarterly Life Sciences sector report, ‘Rude Health: COVID-19 Diagnostics’.
COVID-19 testing is likely to peak in 2021 but will continue to see strong demand into 2022 and beyond as a result of the logistical hurdles in vaccinating the global population as well as the uncertainty around how long vaccine jabs provide immunity and their effectiveness against new COVID strains.
The report looks at the different types of COVID-19 diagnostic technologies and the companies utilizing them. PCR testing is the most common type of testing, providing the highest levels of accuracy, but carries the downsides of being expensive and requiring experienced professionals, with results that can days to process depending on the lab. Companies offering or developing PCR tests include Novacyt, Yourgene and genedrive.
Lateral Flow Diagnostics, on the other hand, can provide cheap and rapid results (within 15 minutes) and can be administered without training, but are not as accurate as other technologies. Companies offering/developing COVID-19 lateral flow diagnostics include Avacta, Mologic-Omega Diagnostics and Immunodiagnostic systems.
...The demand for testing is so high that all processes, regardless of their specific advantages and disadvantages will continue to be needed over a busy 2021. FinnCap highlights AIM listed and private companies, Avacta (AVCT), Novacyte (NCYT), Omega Diagnostics (ODX), genedrive (GDR) and OptiGene among them, and discusses the technologies they have employed and the tests that they have developed or are developing.
Arshad Ahad, Research Analyst, Life Sciences, at finnCap, commented: “The COVID-19 diagnostics sector was at the forefront of international attention in 2020 as the primary weapon to fight the pandemic. The encouraging progress on vaccines has prompted fears over the sustainability of this market; however, we believe these fears are unwarranted. We believe the market has yet to peak and will do so in 2021, but will remain strong into 2022 and beyond. Overall, it is likely that COVID-19 will be a part of our lives for years to come and may even be a perpetual presence – and as long as this
We will have a great day tomorrow When the price correct.
Technically it was a fantastic setup 10 days crossing the 200-day moving average (the Golden Cross).
This will be bouncing off the 50-day moving average today.
@ allah4uk - You Moron you forgot you're using the wrong account (rbr08).
Lloyd was thanking rbr08
Get off this board you Fraudster (deramper)
Omega Diagnostics shows its ready to answer the government’s call for lateral flow tests
Omega Diagnostics has today shown that it is preparing to answer the government’s call to produce up to 2 million COVID-19 lateral flow tests per day from British manufacturers.
Earlier today, it was confirmed that the government is on the search for providers to source and scale British manufacturing capability in the area – with a view to an April 2021 timeframe and potentially easing lockdown restrictions (COVID stocks soar as UK targets 2m British made rapid tests per day).
Omega Diagnostics ready to answer the call
Soon after the news circulated of the government’s intent to scale up domestic lateral flow tests and a fresh study that shown their importance, Omega Diagnostics looked to confirm its credentials by noting that it should be ready to produce 2m tests per week by April 2021.
While April 2021 was a timeframe that Omega Diagnostics was always working to, the news today that consultants and the government are also working to this timeframe is a promising teaser for investors. Likewise, investors will take continued faith in the fact that Omega Diagnostics is a member of the UK Rapid Test Consortrium and that fellow member Abingdon Health recently listed on the stock market.
The diagnostics specialist confirmed that is looking to help answer the government’s call and the progress it was making behind the scenes:
Ask yourself why increase the capacity if you do not expect an order?
We remain on target to increase capacity to 2m lateral flow tests a week by April.
Manufacturing such specialist products requires the right production capabilities, and the right machines - in the right space.
Our Alva site has been a hive of activity as we scale up…
#ODX
https://twitter.com/OmegaDiagnostic/status/1352298721199972352
ABDX when up 15% on this news yesterday - so today was an overreaction.
https://www.lse.co.uk/rns/ABDX/trading-update-u5yhu2c3vj5hd72.html
Department of Health and Social Care
Abingdon is pleased to report that it, along with UK-RTC consortium partners, completed the delivery of an order of 1 million AbC-19 anti-spike IgG devices to the Department of Health and Social Care (DHSC) on 8 January 2021. Regarding the current DHSC contract, as noted previously, this will expire on 14 February 2021 and, in-line with the Government's shift to a dynamic purchasing strategy, the Board expects that any future orders will be received via an application by the Company to future DHSC tender notices.
International approvals for the AbC-19TM Rapid Test
The Company is continuing to manufacture the AbC-19TM Rapid Test in anticipation of additional orders and to that end Abingdon's regulatory department is currently working with UK-RTC partners on regulatory approval in a total of 27 territories. As part of this regulatory approvals process, the Company continues to provide data to the US FDA ("Food and Drug Administration) to allow regulatory approval and in consultation with the FDA has provided additional performance data of the AbC-19TM Rapid Test versus PCR testing via a re-submission. The FDA has asked for additional data relating to PCR testing versus on-site finger-stick blood samples to allow focus on remote, or point-of-care testing which the Company expects to submit within four weeks.
AbC-19TM Rapid Test compatibility with vaccines
The Company believes that as an IgG neutralising antibody test, the AbC-19TM Rapid Test has a key role to play in mitigating the impact of the pandemic. The Company continues to work closely with commercial and academic partners to build the data set(s) around the use-case for the AbC-19TM Rapid Test alongside vaccines, and these will be published in due course.
Contract manufacturing for partners
Abingdon is pleased to report that one of its international contract service customers has received a CE mark for professional use for its COVID-19 lateral flow antigen test. The Company is now working closely with this partner regarding the scale-up of manufacturing to meet anticipated demand for this test. Furthermore, the Company continues to work with a number of other COVID-19 antigen test contract service partners with products in development.
The Company expects to complete delivery of an order for 1 million devices for its PCRD rapid test in February 2021. In this case, Abingdon's PCRD nucleic acid lateral flow immunoassay is being used alongside on-site isothermal amplification to create a near-patient testing molecular testing solution for the presence of the COVID-19 virus. Abingdon's partner is currently going through the FDA-EUA process.
We continue to support existing (non-COVID-19) manufacturing customers and we continue to work on a range of (non-COVID-19)
A welcome clarification from
@Abingdon_Health
:
https://londonstockexchange.com/news-article/ABDX/media-clarification/14843058
Round pushpin The outlook for Omega Diagnostics remains unchanged, and we continue to be very excited about future prospects.
https://twitter.com/OmegaDiagnostic/status/1354503879732424708
#ODX
Great Day guys...!
Really proud that you bought and made a profit. £5+ strong
This is a great opportunity to buy .
Don’t fear the market pull-back... I have added more today.
Instead, aim to turn it to your advantage by holding onto your existing investments and picking up a few potential bargains as well.
Why would they be increasing the capacity for manufacturing?
Look at the hint on Twitter yesterday?
https://twitter.com/OmegaDiagnostic
COVID-19 TESTING SECTOR DEMAND SET TO CONTINUE AMID VACCINE ROLLOUT
Https://www.pharmiweb.com/press-release/2021-01-21/covid-19-testing-sector-demand-set-to-continue-amid-vaccine-rollout
London 21 January 2021 – The diagnostics sector will continue to see growth in 2021 as demand for COVID-19 testing continues to surge. It has been suggested that to ensure effective disease control, the UK alone would require 120m tests per month. Global demand exceeds supply, providing opportunities for existing diagnostics providers and newcomers alike. The diagnostics sector remains a high-growth area, at a time when most other sectors are experiencing disruptions due to the pandemic.
These are the findings of finnCap’s new quarterly Life Sciences sector report, ‘Rude Health: COVID-19 Diagnostics’.
COVID-19 testing is likely to peak in 2021 but will continue to see strong demand into 2022 and beyond as a result of the logistical hurdles in vaccinating the global population as well as the uncertainty around how long vaccine jabs provide immunity and their effectiveness against new COVID strains.
The report looks at the different types of COVID-19 diagnostic technologies and the companies utilizing them. PCR testing is the most common type of testing, providing the highest levels of accuracy, but carries the downsides of being expensive and requiring experienced professionals, with results that can days to process depending on the lab. Companies offering or developing PCR tests include Novacyt, Yourgene and genedrive.
Lateral Flow Diagnostics, on the other hand, can provide cheap and rapid results (within 15 minutes) and can be administered without training, but are not as accurate as other technologies. Companies offering/developing COVID-19 lateral flow diagnostics include Avacta, Mologic-Omega Diagnostics and Immunodiagnostic systems.
...The demand for testing is so high that all processes, regardless of their specific advantages and disadvantages will continue to be needed over a busy 2021. FinnCap highlights AIM listed and private companies, Avacta (AVCT), Novacyte (NCYT), Omega Diagnostics (ODX), genedrive (GDR) and OptiGene among them, and discusses the technologies they have employed and the tests that they have developed or are developing.
Arshad Ahad, Research Analyst, Life Sciences, at finnCap, commented: “The COVID-19 diagnostics sector was at the forefront of international attention in 2020 as the primary weapon to fight the pandemic. The encouraging progress on vaccines has prompted fears over the sustainability of this market; however, we believe these fears are unwarranted. We believe the market has yet to peak and will do so in 2021, but will remain strong into 2022 and beyond. Overall, it is likely that COVID-19 will be a part of our lives for years to come and may even be a perpetual presence – and as long as this remains the case, COVID-19 testing will be an import
I will take them from you.
@ Satallite - I have to agree it was clear manipulation sp today.
MM need cheap shares.
The demand for covid tests outstripping supply.
ODX is a British company that could fulfill the governments 2 million testing target
https://www.pharmiweb.com/press-release/2021-01-21/covid-19-testing-sector-demand-set-to-continue-amid-vaccine-rollout
This is a great opportunity to buy .
Don’t fear the market pull-back... I have added more today.
Instead, aim to turn it to your advantage by holding onto your existing investments and picking up a few potential bargains as well.
Why would they be increasing the capacity for manufacturing?
Look at the hint on Twitter yesterday?
https://twitter.com/OmegaDiagnostic
58.00 +9.00 +18.37% :-) great day
Volume: 3,575,572 Bid/Ask: 55.00 / 59.00
WOW ... 58.96 +9.96 +20.33%
Volume: 3,178,297 Bid/Ask: 57.00 / 59.00
£5 would make same MC as others.
I can't see any fake news. Sysmex (distributor of GDR) has won a massive contract.
Just look at the below links. buy-in before the news lands anytime now.
In light of the increasing numbers of COVID-19 cases throughout the US and the need to expand capacity for COVID-19 testing during the public health emergency, the FDA has stated that it does not object to a commercial manufacturer's development and distribution of SARS-CoV-2 test kits for specimen testing for a reasonable period of time, where the test has been validated and while the manufacturer has made an Emergency Use Authorization request, where the manufacturer gives appropriate notification of validation to FDA, and where the manufacturer provides instructions for use of the test and posts data about the test's performance characteristics on the manufacturer's website.
https://twitter.com/snooptrades/status/1354332450726551554?s=19
https://www.sysmex-europe.com/n/products/diagnostics/sars-cov-2.html